nodes	percent_of_prediction	percent_of_DWPC	metapath
Valsartan—ALB—multiple sclerosis	0.467	1	CbGaD
Valsartan—SLCO1B3—Methotrexate—multiple sclerosis	0.0997	0.364	CbGbCtD
Valsartan—ALB—Prednisone—multiple sclerosis	0.0634	0.231	CbGbCtD
Valsartan—SLCO1B1—Methotrexate—multiple sclerosis	0.0581	0.212	CbGbCtD
Valsartan—ALB—Methotrexate—multiple sclerosis	0.0318	0.116	CbGbCtD
Valsartan—CYP2C9—Dexamethasone—multiple sclerosis	0.0213	0.0778	CbGbCtD
Valsartan—AGTR1—GPCR ligand binding—S1PR1—multiple sclerosis	0.000361	0.00535	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—CD80—multiple sclerosis	0.000359	0.00532	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL13—multiple sclerosis	0.00035	0.00518	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCR1—multiple sclerosis	0.00035	0.00518	CbGpPWpGaD
Valsartan—AGTR1—Peptide ligand-binding receptors—CXCR3—multiple sclerosis	0.000346	0.00511	CbGpPWpGaD
Valsartan—SLCO1B1—Bile acid and bile salt metabolism—ALB—multiple sclerosis	0.000342	0.00506	CbGpPWpGaD
Valsartan—AGTR1—Peptide ligand-binding receptors—CCR2—multiple sclerosis	0.000336	0.00497	CbGpPWpGaD
Valsartan—SLCO1B1—Transport of vitamins, nucleosides, and related molecules—ALB—multiple sclerosis	0.000328	0.00485	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—GPR65—multiple sclerosis	0.000291	0.00431	CbGpPWpGaD
Valsartan—SLCO1B3—SLC-mediated transmembrane transport—SLC11A1—multiple sclerosis	0.000291	0.00431	CbGpPWpGaD
Valsartan—ALB—Lipoprotein metabolism—APOE—multiple sclerosis	0.000289	0.00428	CbGpPWpGaD
Valsartan—Syncope—Methylprednisolone—multiple sclerosis	0.000287	0.00151	CcSEcCtD
Valsartan—Connective tissue disorder—Prednisone—multiple sclerosis	0.000286	0.0015	CcSEcCtD
Valsartan—Anaphylactic shock—Prednisolone—multiple sclerosis	0.000285	0.00149	CcSEcCtD
Valsartan—Oedema—Prednisolone—multiple sclerosis	0.000285	0.00149	CcSEcCtD
Valsartan—Neutropenia—Methotrexate—multiple sclerosis	0.000284	0.00149	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—IFNG—multiple sclerosis	0.000284	0.0042	CbGpPWpGaD
Valsartan—Dizziness—Azathioprine—multiple sclerosis	0.000284	0.00149	CcSEcCtD
Valsartan—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000284	0.00149	CcSEcCtD
Valsartan—Upper respiratory tract infection—Methotrexate—multiple sclerosis	0.000283	0.00148	CcSEcCtD
Valsartan—Loss of consciousness—Triamcinolone—multiple sclerosis	0.000282	0.00148	CcSEcCtD
Valsartan—Loss of consciousness—Methylprednisolone—multiple sclerosis	0.000282	0.00148	CcSEcCtD
Valsartan—Shock—Prednisolone—multiple sclerosis	0.00028	0.00147	CcSEcCtD
Valsartan—Erectile dysfunction—Methotrexate—multiple sclerosis	0.00028	0.00147	CcSEcCtD
Valsartan—Cough—Triamcinolone—multiple sclerosis	0.00028	0.00147	CcSEcCtD
Valsartan—AGTR1—GPCRs, Class A Rhodopsin-like—PTGER4—multiple sclerosis	0.00028	0.00414	CbGpPWpGaD
Valsartan—SLCO1B1—SLC-mediated transmembrane transport—SLC30A7—multiple sclerosis	0.00028	0.00414	CbGpPWpGaD
Valsartan—AGTR1—Peptide ligand-binding receptors—CXCL10—multiple sclerosis	0.000279	0.00413	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	0.000279	0.00413	CbGpPWpGaD
Valsartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MAPK1—multiple sclerosis	0.000279	0.00412	CbGpPWpGaD
Valsartan—Photosensitivity reaction—Methotrexate—multiple sclerosis	0.000278	0.00146	CcSEcCtD
Valsartan—Urticaria—Mitoxantrone—multiple sclerosis	0.000276	0.00145	CcSEcCtD
Valsartan—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000275	0.00144	CcSEcCtD
Valsartan—Myalgia—Triamcinolone—multiple sclerosis	0.000273	0.00143	CcSEcCtD
Valsartan—Vomiting—Azathioprine—multiple sclerosis	0.000273	0.00143	CcSEcCtD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000273	0.00404	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000273	0.00404	CbGpPWpGaD
Valsartan—Myalgia—Methylprednisolone—multiple sclerosis	0.000273	0.00143	CcSEcCtD
Valsartan—Arthralgia—Methylprednisolone—multiple sclerosis	0.000273	0.00143	CcSEcCtD
Valsartan—Anxiety—Methylprednisolone—multiple sclerosis	0.000272	0.00142	CcSEcCtD
Valsartan—Infestation—Methotrexate—multiple sclerosis	0.000271	0.00142	CcSEcCtD
Valsartan—Infestation NOS—Methotrexate—multiple sclerosis	0.000271	0.00142	CcSEcCtD
Valsartan—Rash—Azathioprine—multiple sclerosis	0.000271	0.00142	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000271	0.00142	CcSEcCtD
Valsartan—Dermatitis—Azathioprine—multiple sclerosis	0.000271	0.00142	CcSEcCtD
Valsartan—AGTR1—GPCRs, Class A Rhodopsin-like—CXCR3—multiple sclerosis	0.000271	0.004	CbGpPWpGaD
Valsartan—Headache—Azathioprine—multiple sclerosis	0.000269	0.00141	CcSEcCtD
Valsartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000267	0.00396	CbGpPWpGaD
Valsartan—Dry mouth—Triamcinolone—multiple sclerosis	0.000267	0.0014	CcSEcCtD
Valsartan—Renal failure—Methotrexate—multiple sclerosis	0.000267	0.0014	CcSEcCtD
Valsartan—AGTR1—GPCR ligand binding—CXCL13—multiple sclerosis	0.000266	0.00394	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—CCR1—multiple sclerosis	0.000266	0.00394	CbGpPWpGaD
Valsartan—Angioedema—Betamethasone—multiple sclerosis	0.000266	0.00139	CcSEcCtD
Valsartan—Angioedema—Dexamethasone—multiple sclerosis	0.000266	0.00139	CcSEcCtD
Valsartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—multiple sclerosis	0.000265	0.00392	CbGpPWpGaD
Valsartan—Angiopathy—Prednisone—multiple sclerosis	0.000264	0.00139	CcSEcCtD
Valsartan—Immune system disorder—Prednisone—multiple sclerosis	0.000263	0.00138	CcSEcCtD
Valsartan—AGTR1—GPCRs, Class A Rhodopsin-like—CCR2—multiple sclerosis	0.000263	0.00389	CbGpPWpGaD
Valsartan—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.000262	0.00137	CcSEcCtD
Valsartan—Oedema—Triamcinolone—multiple sclerosis	0.000262	0.00137	CcSEcCtD
Valsartan—Vertigo—Betamethasone—multiple sclerosis	0.000262	0.00137	CcSEcCtD
Valsartan—Vertigo—Dexamethasone—multiple sclerosis	0.000262	0.00137	CcSEcCtD
Valsartan—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.000261	0.00137	CcSEcCtD
Valsartan—Syncope—Betamethasone—multiple sclerosis	0.000261	0.00137	CcSEcCtD
Valsartan—Syncope—Dexamethasone—multiple sclerosis	0.000261	0.00137	CcSEcCtD
Valsartan—Infection—Triamcinolone—multiple sclerosis	0.00026	0.00136	CcSEcCtD
Valsartan—Infection—Methylprednisolone—multiple sclerosis	0.00026	0.00136	CcSEcCtD
Valsartan—Shock—Triamcinolone—multiple sclerosis	0.000258	0.00135	CcSEcCtD
Valsartan—Insomnia—Prednisolone—multiple sclerosis	0.000258	0.00135	CcSEcCtD
Valsartan—Alopecia—Prednisone—multiple sclerosis	0.000257	0.00135	CcSEcCtD
Valsartan—Shock—Methylprednisolone—multiple sclerosis	0.000257	0.00135	CcSEcCtD
Valsartan—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000256	0.00134	CcSEcCtD
Valsartan—Loss of consciousness—Betamethasone—multiple sclerosis	0.000256	0.00134	CcSEcCtD
Valsartan—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000256	0.00134	CcSEcCtD
Valsartan—Epistaxis—Methotrexate—multiple sclerosis	0.000256	0.00134	CcSEcCtD
Valsartan—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000256	0.00134	CcSEcCtD
Valsartan—Paraesthesia—Prednisolone—multiple sclerosis	0.000256	0.00134	CcSEcCtD
Valsartan—Mental disorder—Prednisone—multiple sclerosis	0.000255	0.00134	CcSEcCtD
Valsartan—Nausea—Azathioprine—multiple sclerosis	0.000255	0.00134	CcSEcCtD
Valsartan—Skin disorder—Methylprednisolone—multiple sclerosis	0.000254	0.00133	CcSEcCtD
Valsartan—Malnutrition—Prednisone—multiple sclerosis	0.000254	0.00133	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—IL1B—multiple sclerosis	0.000253	0.00375	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—IL2—multiple sclerosis	0.000253	0.00374	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL3—multiple sclerosis	0.000249	0.00369	CbGpPWpGaD
Valsartan—Asthenia—Mitoxantrone—multiple sclerosis	0.000249	0.00131	CcSEcCtD
Valsartan—Myalgia—Betamethasone—multiple sclerosis	0.000248	0.0013	CcSEcCtD
Valsartan—Myalgia—Dexamethasone—multiple sclerosis	0.000248	0.0013	CcSEcCtD
Valsartan—Anxiety—Dexamethasone—multiple sclerosis	0.000247	0.0013	CcSEcCtD
Valsartan—Anxiety—Betamethasone—multiple sclerosis	0.000247	0.0013	CcSEcCtD
Valsartan—Haemoglobin—Methotrexate—multiple sclerosis	0.000245	0.00128	CcSEcCtD
Valsartan—Hypotension—Methylprednisolone—multiple sclerosis	0.000244	0.00128	CcSEcCtD
Valsartan—Hepatitis—Methotrexate—multiple sclerosis	0.000244	0.00128	CcSEcCtD
Valsartan—Haemorrhage—Methotrexate—multiple sclerosis	0.000244	0.00128	CcSEcCtD
Valsartan—AGTR1—GPCRs, Class A Rhodopsin-like—CNR1—multiple sclerosis	0.000243	0.00359	CbGpPWpGaD
Valsartan—Pharyngitis—Methotrexate—multiple sclerosis	0.000242	0.00127	CcSEcCtD
Valsartan—Urinary tract disorder—Methotrexate—multiple sclerosis	0.00024	0.00126	CcSEcCtD
Valsartan—AGTR1—Peptide ligand-binding receptors—CCL5—multiple sclerosis	0.00024	0.00356	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—PTGER4—multiple sclerosis	0.00024	0.00355	CbGpPWpGaD
Valsartan—Vision blurred—Prednisone—multiple sclerosis	0.000239	0.00125	CcSEcCtD
Valsartan—Urethral disorder—Methotrexate—multiple sclerosis	0.000239	0.00125	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000239	0.00125	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000238	0.00125	CcSEcCtD
Valsartan—Oedema—Betamethasone—multiple sclerosis	0.000238	0.00125	CcSEcCtD
Valsartan—Oedema—Dexamethasone—multiple sclerosis	0.000238	0.00125	CcSEcCtD
Valsartan—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000238	0.00125	CcSEcCtD
Valsartan—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000238	0.00125	CcSEcCtD
Valsartan—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000238	0.00125	CcSEcCtD
Valsartan—Insomnia—Triamcinolone—multiple sclerosis	0.000237	0.00124	CcSEcCtD
Valsartan—Insomnia—Methylprednisolone—multiple sclerosis	0.000236	0.00124	CcSEcCtD
Valsartan—Infection—Betamethasone—multiple sclerosis	0.000236	0.00124	CcSEcCtD
Valsartan—Infection—Dexamethasone—multiple sclerosis	0.000236	0.00124	CcSEcCtD
Valsartan—Paraesthesia—Triamcinolone—multiple sclerosis	0.000235	0.00123	CcSEcCtD
Valsartan—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000235	0.00123	CcSEcCtD
Valsartan—Shock—Betamethasone—multiple sclerosis	0.000234	0.00123	CcSEcCtD
Valsartan—Shock—Dexamethasone—multiple sclerosis	0.000234	0.00123	CcSEcCtD
Valsartan—Dyspnoea—Triamcinolone—multiple sclerosis	0.000234	0.00122	CcSEcCtD
Valsartan—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000233	0.00122	CcSEcCtD
Valsartan—Nervous system disorder—Betamethasone—multiple sclerosis	0.000233	0.00122	CcSEcCtD
Valsartan—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000233	0.00122	CcSEcCtD
Valsartan—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000233	0.00122	CcSEcCtD
Valsartan—Angioedema—Prednisone—multiple sclerosis	0.000232	0.00121	CcSEcCtD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCR3—multiple sclerosis	0.000232	0.00343	CbGpPWpGaD
Valsartan—Dyspepsia—Triamcinolone—multiple sclerosis	0.000231	0.00121	CcSEcCtD
Valsartan—ALB—Vitamin B12 Metabolism—CCL5—multiple sclerosis	0.000231	0.00341	CbGpPWpGaD
Valsartan—Dyspepsia—Methylprednisolone—multiple sclerosis	0.00023	0.00121	CcSEcCtD
Valsartan—Vertigo—Prednisone—multiple sclerosis	0.000228	0.00119	CcSEcCtD
Valsartan—Syncope—Prednisone—multiple sclerosis	0.000227	0.00119	CcSEcCtD
Valsartan—Anorexia—Betamethasone—multiple sclerosis	0.000227	0.00119	CcSEcCtD
Valsartan—Anorexia—Dexamethasone—multiple sclerosis	0.000227	0.00119	CcSEcCtD
Valsartan—Urticaria—Prednisolone—multiple sclerosis	0.000226	0.00119	CcSEcCtD
Valsartan—Cardiac disorder—Methotrexate—multiple sclerosis	0.000226	0.00118	CcSEcCtD
Valsartan—Fatigue—Triamcinolone—multiple sclerosis	0.000226	0.00118	CcSEcCtD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCR2—multiple sclerosis	0.000225	0.00334	CbGpPWpGaD
Valsartan—Fatigue—Methylprednisolone—multiple sclerosis	0.000225	0.00118	CcSEcCtD
Valsartan—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOE—multiple sclerosis	0.000225	0.00333	CbGpPWpGaD
Valsartan—CYP2C9—Biological oxidations—CYP27B1—multiple sclerosis	0.000223	0.00331	CbGpPWpGaD
Valsartan—CYP2C9—Biological oxidations—CYP24A1—multiple sclerosis	0.000223	0.00331	CbGpPWpGaD
Valsartan—Loss of consciousness—Prednisone—multiple sclerosis	0.000223	0.00117	CcSEcCtD
Valsartan—Hypotension—Betamethasone—multiple sclerosis	0.000222	0.00116	CcSEcCtD
Valsartan—Hypotension—Dexamethasone—multiple sclerosis	0.000222	0.00116	CcSEcCtD
Valsartan—Angiopathy—Methotrexate—multiple sclerosis	0.000221	0.00116	CcSEcCtD
Valsartan—Vomiting—Mitoxantrone—multiple sclerosis	0.000221	0.00116	CcSEcCtD
Valsartan—CYP2C9—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.00022	0.00326	CbGpPWpGaD
Valsartan—CYP2C9—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.00022	0.00326	CbGpPWpGaD
Valsartan—Immune system disorder—Methotrexate—multiple sclerosis	0.00022	0.00115	CcSEcCtD
Valsartan—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000219	0.00115	CcSEcCtD
Valsartan—Rash—Mitoxantrone—multiple sclerosis	0.000219	0.00115	CcSEcCtD
Valsartan—Dermatitis—Mitoxantrone—multiple sclerosis	0.000219	0.00115	CcSEcCtD
Valsartan—Headache—Mitoxantrone—multiple sclerosis	0.000218	0.00114	CcSEcCtD
Valsartan—AGTR1—Peptide ligand-binding receptors—CCR5—multiple sclerosis	0.000217	0.0032	CbGpPWpGaD
Valsartan—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000217	0.00114	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000217	0.00114	CcSEcCtD
Valsartan—Myalgia—Prednisone—multiple sclerosis	0.000216	0.00113	CcSEcCtD
Valsartan—Arthralgia—Prednisone—multiple sclerosis	0.000216	0.00113	CcSEcCtD
Valsartan—Anxiety—Prednisone—multiple sclerosis	0.000215	0.00113	CcSEcCtD
Valsartan—Alopecia—Methotrexate—multiple sclerosis	0.000215	0.00113	CcSEcCtD
Valsartan—Insomnia—Dexamethasone—multiple sclerosis	0.000215	0.00113	CcSEcCtD
Valsartan—Insomnia—Betamethasone—multiple sclerosis	0.000215	0.00113	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000214	0.00112	CcSEcCtD
Valsartan—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000214	0.00112	CcSEcCtD
Valsartan—Paraesthesia—Betamethasone—multiple sclerosis	0.000213	0.00112	CcSEcCtD
Valsartan—Paraesthesia—Dexamethasone—multiple sclerosis	0.000213	0.00112	CcSEcCtD
Valsartan—Mental disorder—Methotrexate—multiple sclerosis	0.000213	0.00112	CcSEcCtD
Valsartan—Malnutrition—Methotrexate—multiple sclerosis	0.000212	0.00111	CcSEcCtD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	0.000212	0.00313	CbGpPWpGaD
Valsartan—ALB—SLC-mediated transmembrane transport—SLC15A2—multiple sclerosis	0.000211	0.00312	CbGpPWpGaD
Valsartan—Hypersensitivity—Prednisolone—multiple sclerosis	0.00021	0.0011	CcSEcCtD
Valsartan—Dyspepsia—Betamethasone—multiple sclerosis	0.000209	0.0011	CcSEcCtD
Valsartan—Dyspepsia—Dexamethasone—multiple sclerosis	0.000209	0.0011	CcSEcCtD
Valsartan—Urticaria—Triamcinolone—multiple sclerosis	0.000208	0.00109	CcSEcCtD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CNR1—multiple sclerosis	0.000208	0.00308	CbGpPWpGaD
Valsartan—Urticaria—Methylprednisolone—multiple sclerosis	0.000208	0.00109	CcSEcCtD
Valsartan—Dysgeusia—Methotrexate—multiple sclerosis	0.000208	0.00109	CcSEcCtD
Valsartan—Oedema—Prednisone—multiple sclerosis	0.000207	0.00109	CcSEcCtD
Valsartan—Anaphylactic shock—Prednisone—multiple sclerosis	0.000207	0.00109	CcSEcCtD
Valsartan—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000207	0.00108	CcSEcCtD
Valsartan—Decreased appetite—Betamethasone—multiple sclerosis	0.000207	0.00108	CcSEcCtD
Valsartan—Decreased appetite—Dexamethasone—multiple sclerosis	0.000207	0.00108	CcSEcCtD
Valsartan—Nausea—Mitoxantrone—multiple sclerosis	0.000206	0.00108	CcSEcCtD
Valsartan—Infection—Prednisone—multiple sclerosis	0.000206	0.00108	CcSEcCtD
Valsartan—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000205	0.00108	CcSEcCtD
Valsartan—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000205	0.00108	CcSEcCtD
Valsartan—Back pain—Methotrexate—multiple sclerosis	0.000205	0.00107	CcSEcCtD
Valsartan—Fatigue—Betamethasone—multiple sclerosis	0.000205	0.00107	CcSEcCtD
Valsartan—Fatigue—Dexamethasone—multiple sclerosis	0.000205	0.00107	CcSEcCtD
Valsartan—AGTR1—GPCR downstream signaling—S1PR1—multiple sclerosis	0.000204	0.00302	CbGpPWpGaD
Valsartan—Shock—Prednisone—multiple sclerosis	0.000204	0.00107	CcSEcCtD
Valsartan—Nervous system disorder—Prednisone—multiple sclerosis	0.000203	0.00106	CcSEcCtD
Valsartan—Skin disorder—Prednisone—multiple sclerosis	0.000201	0.00105	CcSEcCtD
Valsartan—Vision blurred—Methotrexate—multiple sclerosis	0.0002	0.00105	CcSEcCtD
Valsartan—Anorexia—Prednisone—multiple sclerosis	0.000197	0.00103	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—TGFB1—multiple sclerosis	0.000197	0.00291	CbGpPWpGaD
Valsartan—SLCO1B1—SLC-mediated transmembrane transport—SLC11A1—multiple sclerosis	0.000196	0.00289	CbGpPWpGaD
Valsartan—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000194	0.00102	CcSEcCtD
Valsartan—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000194	0.00102	CcSEcCtD
Valsartan—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000193	0.00101	CcSEcCtD
Valsartan—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000193	0.00101	CcSEcCtD
Valsartan—ALB—Lipid and lipoprotein metabolism—APOE—multiple sclerosis	0.000192	0.00284	CbGpPWpGaD
Valsartan—Vertigo—Methotrexate—multiple sclerosis	0.00019	0.000998	CcSEcCtD
Valsartan—AGTR1—GPCR ligand binding—CCL3—multiple sclerosis	0.00019	0.00281	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—APOE—multiple sclerosis	0.000189	0.0028	CbGpPWpGaD
Valsartan—Urticaria—Betamethasone—multiple sclerosis	0.000189	0.00099	CcSEcCtD
Valsartan—Urticaria—Dexamethasone—multiple sclerosis	0.000189	0.00099	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000189	0.000989	CcSEcCtD
Valsartan—Dizziness—Prednisolone—multiple sclerosis	0.000188	0.000987	CcSEcCtD
Valsartan—Asthenia—Triamcinolone—multiple sclerosis	0.000188	0.000985	CcSEcCtD
Valsartan—Abdominal pain—Betamethasone—multiple sclerosis	0.000188	0.000985	CcSEcCtD
Valsartan—Abdominal pain—Dexamethasone—multiple sclerosis	0.000188	0.000985	CcSEcCtD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	0.000188	0.00278	CbGpPWpGaD
Valsartan—Asthenia—Methylprednisolone—multiple sclerosis	0.000188	0.000983	CcSEcCtD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	0.000187	0.00277	CbGpPWpGaD
Valsartan—Insomnia—Prednisone—multiple sclerosis	0.000187	0.000981	CcSEcCtD
Valsartan—Paraesthesia—Prednisone—multiple sclerosis	0.000186	0.000974	CcSEcCtD
Valsartan—AGTR1—Signaling by GPCR—S1PR1—multiple sclerosis	0.000185	0.00274	CbGpPWpGaD
Valsartan—Pruritus—Triamcinolone—multiple sclerosis	0.000185	0.000971	CcSEcCtD
Valsartan—Cough—Methotrexate—multiple sclerosis	0.000185	0.00097	CcSEcCtD
Valsartan—Pruritus—Methylprednisolone—multiple sclerosis	0.000185	0.000969	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—TNF—multiple sclerosis	0.000184	0.00272	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000183	0.00271	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000183	0.00271	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—PTGER4—multiple sclerosis	0.000183	0.0027	CbGpPWpGaD
Valsartan—Dyspepsia—Prednisone—multiple sclerosis	0.000182	0.000955	CcSEcCtD
Valsartan—ALB—Platelet activation, signaling and aggregation—PLEK—multiple sclerosis	0.000182	0.00269	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—IL4—multiple sclerosis	0.000182	0.00269	CbGpPWpGaD
Valsartan—Myalgia—Methotrexate—multiple sclerosis	0.00018	0.000946	CcSEcCtD
Valsartan—Chest pain—Methotrexate—multiple sclerosis	0.00018	0.000946	CcSEcCtD
Valsartan—Arthralgia—Methotrexate—multiple sclerosis	0.00018	0.000946	CcSEcCtD
Valsartan—Decreased appetite—Prednisone—multiple sclerosis	0.00018	0.000943	CcSEcCtD
Valsartan—Rash—Prednisolone—multiple sclerosis	0.00018	0.000941	CcSEcCtD
Valsartan—Dermatitis—Prednisolone—multiple sclerosis	0.000179	0.000941	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000179	0.000939	CcSEcCtD
Valsartan—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000179	0.000937	CcSEcCtD
Valsartan—Fatigue—Prednisone—multiple sclerosis	0.000178	0.000935	CcSEcCtD
Valsartan—Headache—Prednisolone—multiple sclerosis	0.000178	0.000935	CcSEcCtD
Valsartan—ALB—Vitamin B12 Metabolism—ICAM1—multiple sclerosis	0.000178	0.00263	CbGpPWpGaD
Valsartan—Constipation—Prednisone—multiple sclerosis	0.000177	0.000928	CcSEcCtD
Valsartan—AGTR1—GPCR ligand binding—CXCR3—multiple sclerosis	0.000176	0.00261	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—RGS1—multiple sclerosis	0.000174	0.00257	CbGpPWpGaD
Valsartan—Dizziness—Triamcinolone—multiple sclerosis	0.000173	0.000908	CcSEcCtD
Valsartan—Anaphylactic shock—Methotrexate—multiple sclerosis	0.000173	0.000907	CcSEcCtD
Valsartan—Dizziness—Methylprednisolone—multiple sclerosis	0.000173	0.000906	CcSEcCtD
Valsartan—SLCO1B3—Metabolism—SRM—multiple sclerosis	0.000173	0.00255	CbGpPWpGaD
Valsartan—Infection—Methotrexate—multiple sclerosis	0.000172	0.000901	CcSEcCtD
Valsartan—AGTR1—GPCR ligand binding—CCR2—multiple sclerosis	0.000172	0.00254	CbGpPWpGaD
Valsartan—Asthenia—Dexamethasone—multiple sclerosis	0.000171	0.000894	CcSEcCtD
Valsartan—Asthenia—Betamethasone—multiple sclerosis	0.000171	0.000894	CcSEcCtD
Valsartan—Nervous system disorder—Methotrexate—multiple sclerosis	0.00017	0.000889	CcSEcCtD
Valsartan—AGTR1—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	0.00017	0.00251	CbGpPWpGaD
Valsartan—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000169	0.000888	CcSEcCtD
Valsartan—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000169	0.000887	CcSEcCtD
Valsartan—AGTR1—Peptide ligand-binding receptors—POMC—multiple sclerosis	0.000169	0.0025	CbGpPWpGaD
Valsartan—Nausea—Prednisolone—multiple sclerosis	0.000169	0.000887	CcSEcCtD
Valsartan—Pruritus—Dexamethasone—multiple sclerosis	0.000168	0.000881	CcSEcCtD
Valsartan—Pruritus—Betamethasone—multiple sclerosis	0.000168	0.000881	CcSEcCtD
Valsartan—Skin disorder—Methotrexate—multiple sclerosis	0.000168	0.000881	CcSEcCtD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—AQP4—multiple sclerosis	0.000167	0.00247	CbGpPWpGaD
Valsartan—Vomiting—Triamcinolone—multiple sclerosis	0.000167	0.000873	CcSEcCtD
Valsartan—Vomiting—Methylprednisolone—multiple sclerosis	0.000166	0.000871	CcSEcCtD
Valsartan—AGTR1—Peptide ligand-binding receptors—CCL2—multiple sclerosis	0.000166	0.00245	CbGpPWpGaD
Valsartan—Rash—Triamcinolone—multiple sclerosis	0.000165	0.000866	CcSEcCtD
Valsartan—Dermatitis—Triamcinolone—multiple sclerosis	0.000165	0.000865	CcSEcCtD
Valsartan—Anorexia—Methotrexate—multiple sclerosis	0.000165	0.000864	CcSEcCtD
Valsartan—Rash—Methylprednisolone—multiple sclerosis	0.000165	0.000864	CcSEcCtD
Valsartan—Dermatitis—Methylprednisolone—multiple sclerosis	0.000165	0.000863	CcSEcCtD
Valsartan—AGTR1—GPCR downstream signaling—GPR65—multiple sclerosis	0.000165	0.00244	CbGpPWpGaD
Valsartan—Urticaria—Prednisone—multiple sclerosis	0.000164	0.000862	CcSEcCtD
Valsartan—Headache—Triamcinolone—multiple sclerosis	0.000164	0.00086	CcSEcCtD
Valsartan—Headache—Methylprednisolone—multiple sclerosis	0.000164	0.000858	CcSEcCtD
Valsartan—Abdominal pain—Prednisone—multiple sclerosis	0.000164	0.000858	CcSEcCtD
Valsartan—Diarrhoea—Betamethasone—multiple sclerosis	0.000163	0.000852	CcSEcCtD
Valsartan—Diarrhoea—Dexamethasone—multiple sclerosis	0.000163	0.000852	CcSEcCtD
Valsartan—Hypotension—Methotrexate—multiple sclerosis	0.000162	0.000847	CcSEcCtD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	0.000161	0.00239	CbGpPWpGaD
Valsartan—ALB—SLC-mediated transmembrane transport—SLC30A7—multiple sclerosis	0.00016	0.00237	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—CCL2—multiple sclerosis	0.000159	0.00235	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—CNR1—multiple sclerosis	0.000158	0.00234	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—RGS1—multiple sclerosis	0.000158	0.00233	CbGpPWpGaD
Valsartan—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000158	0.000826	CcSEcCtD
Valsartan—Dizziness—Betamethasone—multiple sclerosis	0.000157	0.000824	CcSEcCtD
Valsartan—Dizziness—Dexamethasone—multiple sclerosis	0.000157	0.000824	CcSEcCtD
Valsartan—Insomnia—Methotrexate—multiple sclerosis	0.000156	0.00082	CcSEcCtD
Valsartan—Nausea—Triamcinolone—multiple sclerosis	0.000156	0.000816	CcSEcCtD
Valsartan—Paraesthesia—Methotrexate—multiple sclerosis	0.000155	0.000814	CcSEcCtD
Valsartan—Nausea—Methylprednisolone—multiple sclerosis	0.000155	0.000814	CcSEcCtD
Valsartan—Dyspnoea—Methotrexate—multiple sclerosis	0.000154	0.000808	CcSEcCtD
Valsartan—Somnolence—Methotrexate—multiple sclerosis	0.000154	0.000806	CcSEcCtD
Valsartan—Hypersensitivity—Prednisone—multiple sclerosis	0.000153	0.000799	CcSEcCtD
Valsartan—Dyspepsia—Methotrexate—multiple sclerosis	0.000152	0.000798	CcSEcCtD
Valsartan—ALB—Hemostasis—MERTK—multiple sclerosis	0.000152	0.00225	CbGpPWpGaD
Valsartan—ALB—Hemostasis—CD58—multiple sclerosis	0.000152	0.00225	CbGpPWpGaD
Valsartan—ALB—Hemostasis—SELPLG—multiple sclerosis	0.000152	0.00225	CbGpPWpGaD
Valsartan—Vomiting—Betamethasone—multiple sclerosis	0.000151	0.000792	CcSEcCtD
Valsartan—Vomiting—Dexamethasone—multiple sclerosis	0.000151	0.000792	CcSEcCtD
Valsartan—AGTR1—GPCR downstream signaling—CXCL13—multiple sclerosis	0.000151	0.00223	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CCR1—multiple sclerosis	0.000151	0.00223	CbGpPWpGaD
Valsartan—Decreased appetite—Methotrexate—multiple sclerosis	0.00015	0.000788	CcSEcCtD
Valsartan—Rash—Betamethasone—multiple sclerosis	0.00015	0.000786	CcSEcCtD
Valsartan—Rash—Dexamethasone—multiple sclerosis	0.00015	0.000786	CcSEcCtD
Valsartan—Dermatitis—Betamethasone—multiple sclerosis	0.00015	0.000785	CcSEcCtD
Valsartan—Dermatitis—Dexamethasone—multiple sclerosis	0.00015	0.000785	CcSEcCtD
Valsartan—AGTR1—Signaling by GPCR—GPR65—multiple sclerosis	0.000149	0.00221	CbGpPWpGaD
Valsartan—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000149	0.000783	CcSEcCtD
Valsartan—Fatigue—Methotrexate—multiple sclerosis	0.000149	0.000782	CcSEcCtD
Valsartan—Headache—Betamethasone—multiple sclerosis	0.000149	0.000781	CcSEcCtD
Valsartan—Headache—Dexamethasone—multiple sclerosis	0.000149	0.000781	CcSEcCtD
Valsartan—Asthenia—Prednisone—multiple sclerosis	0.000149	0.000778	CcSEcCtD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	0.000148	0.00219	CbGpPWpGaD
Valsartan—Pruritus—Prednisone—multiple sclerosis	0.000146	0.000768	CcSEcCtD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	0.000145	0.00215	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—LINGO1—multiple sclerosis	0.000145	0.00214	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—ICAM1—multiple sclerosis	0.000144	0.00214	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—CXCL10—multiple sclerosis	0.000143	0.00211	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	0.000142	0.0021	CbGpPWpGaD
Valsartan—Diarrhoea—Prednisone—multiple sclerosis	0.000142	0.000742	CcSEcCtD
Valsartan—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000141	0.000741	CcSEcCtD
Valsartan—Nausea—Dexamethasone—multiple sclerosis	0.000141	0.00074	CcSEcCtD
Valsartan—Nausea—Betamethasone—multiple sclerosis	0.000141	0.00074	CcSEcCtD
Valsartan—Urticaria—Methotrexate—multiple sclerosis	0.000137	0.00072	CcSEcCtD
Valsartan—Dizziness—Prednisone—multiple sclerosis	0.000137	0.000717	CcSEcCtD
Valsartan—Abdominal pain—Methotrexate—multiple sclerosis	0.000137	0.000717	CcSEcCtD
Valsartan—AGTR1—Signaling by GPCR—CCR1—multiple sclerosis	0.000137	0.00202	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CXCL13—multiple sclerosis	0.000137	0.00202	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—multiple sclerosis	0.000136	0.00202	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—IFNG—multiple sclerosis	0.000135	0.002	CbGpPWpGaD
Valsartan—Vomiting—Prednisone—multiple sclerosis	0.000132	0.00069	CcSEcCtD
Valsartan—Rash—Prednisone—multiple sclerosis	0.000131	0.000684	CcSEcCtD
Valsartan—Dermatitis—Prednisone—multiple sclerosis	0.00013	0.000683	CcSEcCtD
Valsartan—Headache—Prednisone—multiple sclerosis	0.00013	0.00068	CcSEcCtD
Valsartan—ALB—Folate Metabolism—CCL2—multiple sclerosis	0.000129	0.00191	CbGpPWpGaD
Valsartan—Hypersensitivity—Methotrexate—multiple sclerosis	0.000127	0.000668	CcSEcCtD
Valsartan—AGTR1—Signaling Pathways—TAGAP—multiple sclerosis	0.000125	0.00185	CbGpPWpGaD
Valsartan—Asthenia—Methotrexate—multiple sclerosis	0.000124	0.000651	CcSEcCtD
Valsartan—Nausea—Prednisone—multiple sclerosis	0.000123	0.000644	CcSEcCtD
Valsartan—AGTR1—GPCR ligand binding—CCL5—multiple sclerosis	0.000123	0.00182	CbGpPWpGaD
Valsartan—Pruritus—Methotrexate—multiple sclerosis	0.000122	0.000642	CcSEcCtD
Valsartan—SLCO1B3—Metabolism—CYP27B1—multiple sclerosis	0.000122	0.0018	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CYP24A1—multiple sclerosis	0.000122	0.0018	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—IL1B—multiple sclerosis	0.00012	0.00178	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	0.000119	0.00176	CbGpPWpGaD
Valsartan—Diarrhoea—Methotrexate—multiple sclerosis	0.000118	0.00062	CcSEcCtD
Valsartan—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000117	0.00173	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—SRM—multiple sclerosis	0.000116	0.00172	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—ICAM1—multiple sclerosis	0.000115	0.0017	CbGpPWpGaD
Valsartan—Dizziness—Methotrexate—multiple sclerosis	0.000114	0.0006	CcSEcCtD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.000114	0.00168	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	0.000112	0.00166	CbGpPWpGaD
Valsartan—ALB—SLC-mediated transmembrane transport—SLC11A1—multiple sclerosis	0.000112	0.00165	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GPC5—multiple sclerosis	0.000111	0.00165	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.000111	0.00164	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—CCR5—multiple sclerosis	0.000111	0.00164	CbGpPWpGaD
Valsartan—Vomiting—Methotrexate—multiple sclerosis	0.00011	0.000577	CcSEcCtD
Valsartan—ALB—Folate Metabolism—IFNG—multiple sclerosis	0.00011	0.00163	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—S1PR1—multiple sclerosis	0.00011	0.00162	CbGpPWpGaD
Valsartan—Rash—Methotrexate—multiple sclerosis	0.000109	0.000572	CcSEcCtD
Valsartan—Dermatitis—Methotrexate—multiple sclerosis	0.000109	0.000571	CcSEcCtD
Valsartan—Headache—Methotrexate—multiple sclerosis	0.000108	0.000568	CcSEcCtD
Valsartan—ALB—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	0.000107	0.00159	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—GPC5—multiple sclerosis	0.000107	0.00158	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000105	0.00155	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000105	0.00155	CbGpPWpGaD
Valsartan—SLCO1B3—SLC-mediated transmembrane transport—ALB—multiple sclerosis	0.000105	0.00155	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—PTGER4—multiple sclerosis	0.000103	0.00153	CbGpPWpGaD
Valsartan—Nausea—Methotrexate—multiple sclerosis	0.000103	0.000539	CcSEcCtD
Valsartan—ALB—Selenium Micronutrient Network—CCL2—multiple sclerosis	0.000103	0.00152	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CXCR3—multiple sclerosis	9.97e-05	0.00148	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	9.94e-05	0.00147	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—IL1B—multiple sclerosis	9.8e-05	0.00145	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—IL2—multiple sclerosis	9.77e-05	0.00144	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CCL3—multiple sclerosis	9.74e-05	0.00144	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CCR2—multiple sclerosis	9.7e-05	0.00144	CbGpPWpGaD
Valsartan—CYP2C9—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	9.46e-05	0.0014	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PLEK—multiple sclerosis	9.38e-05	0.00139	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PTGER4—multiple sclerosis	9.38e-05	0.00139	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—RGS1—multiple sclerosis	9.32e-05	0.00138	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—RRM1—multiple sclerosis	9.22e-05	0.00136	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CXCR3—multiple sclerosis	9.06e-05	0.00134	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CNR1—multiple sclerosis	8.95e-05	0.00132	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—GPR65—multiple sclerosis	8.83e-05	0.00131	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CCR2—multiple sclerosis	8.81e-05	0.0013	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—TNF—multiple sclerosis	8.74e-05	0.00129	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—IFNG—multiple sclerosis	8.73e-05	0.00129	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	8.67e-05	0.00128	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—POMC—multiple sclerosis	8.65e-05	0.00128	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	8.58e-05	0.00127	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	8.58e-05	0.00127	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—CCL2—multiple sclerosis	8.46e-05	0.00125	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CYP27B1—multiple sclerosis	8.17e-05	0.00121	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CYP24A1—multiple sclerosis	8.17e-05	0.00121	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CNR1—multiple sclerosis	8.13e-05	0.0012	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	8.12e-05	0.0012	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CXCL13—multiple sclerosis	8.08e-05	0.00119	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCR1—multiple sclerosis	8.08e-05	0.00119	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CXCL10—multiple sclerosis	8.06e-05	0.00119	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	7.98e-05	0.00118	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—IL1B—multiple sclerosis	7.79e-05	0.00115	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GPC5—multiple sclerosis	7.47e-05	0.00111	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CXCL10—multiple sclerosis	7.32e-05	0.00108	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	7.15e-05	0.00106	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—TNF—multiple sclerosis	7.11e-05	0.00105	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—IL6—multiple sclerosis	7.06e-05	0.00104	CbGpPWpGaD
Valsartan—SLCO1B1—SLC-mediated transmembrane transport—ALB—multiple sclerosis	7.04e-05	0.00104	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CCL5—multiple sclerosis	6.94e-05	0.00103	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	6.66e-05	0.000986	CbGpPWpGaD
Valsartan—ALB—Metabolism—SRM—multiple sclerosis	6.63e-05	0.00098	CbGpPWpGaD
Valsartan—ALB—Hemostasis—SELE—multiple sclerosis	6.61e-05	0.000978	CbGpPWpGaD
Valsartan—ALB—Platelet degranulation—TGFB1—multiple sclerosis	6.53e-05	0.000966	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—AQP4—multiple sclerosis	6.42e-05	0.00095	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—IL2RA—multiple sclerosis	6.34e-05	0.000937	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CCL5—multiple sclerosis	6.3e-05	0.000932	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CCR5—multiple sclerosis	6.25e-05	0.000925	CbGpPWpGaD
Valsartan—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—multiple sclerosis	6.22e-05	0.000921	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—RRM1—multiple sclerosis	6.19e-05	0.000916	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—IL2RA—multiple sclerosis	6.16e-05	0.000912	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	6.14e-05	0.000909	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCL3—multiple sclerosis	5.75e-05	0.000851	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—IL6—multiple sclerosis	5.74e-05	0.000849	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CCR5—multiple sclerosis	5.68e-05	0.00084	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	5.68e-05	0.00084	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—TNF—multiple sclerosis	5.65e-05	0.000836	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	5.6e-05	0.000828	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL2RA—multiple sclerosis	5.6e-05	0.000828	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PTGER4—multiple sclerosis	5.54e-05	0.00082	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PGR—multiple sclerosis	5.46e-05	0.000807	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SRM—multiple sclerosis	5.42e-05	0.000802	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CXCR3—multiple sclerosis	5.35e-05	0.000792	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—ALB—multiple sclerosis	5.32e-05	0.000788	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CD28—multiple sclerosis	5.3e-05	0.000784	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—BCHE—multiple sclerosis	5.29e-05	0.000783	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCR2—multiple sclerosis	5.2e-05	0.00077	CbGpPWpGaD
Valsartan—CYP2C9—Biological oxidations—POMC—multiple sclerosis	5.03e-05	0.000743	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—POMC—multiple sclerosis	4.89e-05	0.000723	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	4.8e-05	0.000711	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CNR1—multiple sclerosis	4.8e-05	0.000711	CbGpPWpGaD
Valsartan—ALB—Hemostasis—ITGA4—multiple sclerosis	4.78e-05	0.000707	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IFNB1—multiple sclerosis	4.75e-05	0.000702	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP27B1—multiple sclerosis	4.67e-05	0.000691	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP24A1—multiple sclerosis	4.67e-05	0.000691	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	4.56e-05	0.000675	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—IL6—multiple sclerosis	4.56e-05	0.000675	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—POMC—multiple sclerosis	4.44e-05	0.000656	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CCL2—multiple sclerosis	4.34e-05	0.000642	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CXCL10—multiple sclerosis	4.32e-05	0.00064	CbGpPWpGaD
Valsartan—ALB—Metabolism—GPC5—multiple sclerosis	4.27e-05	0.000632	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	4.13e-05	0.00061	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—TYK2—multiple sclerosis	3.94e-05	0.000583	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP27B1—multiple sclerosis	3.82e-05	0.000565	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP24A1—multiple sclerosis	3.82e-05	0.000565	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CD86—multiple sclerosis	3.78e-05	0.000559	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	3.76e-05	0.000557	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	3.73e-05	0.000552	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCL5—multiple sclerosis	3.72e-05	0.000551	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—IL2—multiple sclerosis	3.71e-05	0.000549	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—IL2—multiple sclerosis	3.61e-05	0.000534	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—ALB—multiple sclerosis	3.58e-05	0.000529	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—BCHE—multiple sclerosis	3.56e-05	0.000526	CbGpPWpGaD
Valsartan—ALB—Metabolism—RRM1—multiple sclerosis	3.54e-05	0.000523	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GPC5—multiple sclerosis	3.49e-05	0.000517	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SPP1—multiple sclerosis	3.45e-05	0.00051	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCR5—multiple sclerosis	3.35e-05	0.000496	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL2RA—multiple sclerosis	3.31e-05	0.000489	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL2—multiple sclerosis	3.28e-05	0.000485	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IL2RA—multiple sclerosis	3.27e-05	0.000483	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—APOE—multiple sclerosis	3.18e-05	0.000471	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—APOE—multiple sclerosis	3.05e-05	0.000451	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	2.9e-05	0.000429	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—RRM1—multiple sclerosis	2.9e-05	0.000428	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	2.84e-05	0.00042	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CD80—multiple sclerosis	2.76e-05	0.000408	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	2.74e-05	0.000406	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—POMC—multiple sclerosis	2.74e-05	0.000405	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—POMC—multiple sclerosis	2.62e-05	0.000388	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCL2—multiple sclerosis	2.56e-05	0.000379	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—MAPK1—multiple sclerosis	2.51e-05	0.000371	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ALB—multiple sclerosis	2.49e-05	0.000369	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	2.36e-05	0.000349	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TYK2—multiple sclerosis	2.33e-05	0.000345	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	2.25e-05	0.000332	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—APOE—multiple sclerosis	2.14e-05	0.000316	CbGpPWpGaD
Valsartan—ALB—Metabolism—BCHE—multiple sclerosis	2.03e-05	0.000301	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL2—multiple sclerosis	1.94e-05	0.000287	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.93e-05	0.000286	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL6—multiple sclerosis	1.93e-05	0.000285	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IL2—multiple sclerosis	1.91e-05	0.000283	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—POMC—multiple sclerosis	1.84e-05	0.000272	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MMP9—multiple sclerosis	1.83e-05	0.000271	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.76e-05	0.00026	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ALB—multiple sclerosis	1.68e-05	0.000248	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—BCHE—multiple sclerosis	1.66e-05	0.000246	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—STAT3—multiple sclerosis	1.63e-05	0.000241	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MYC—multiple sclerosis	1.52e-05	0.000224	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TGFB1—multiple sclerosis	1.51e-05	0.000224	CbGpPWpGaD
Valsartan—ALB—Hemostasis—TGFB1—multiple sclerosis	1.49e-05	0.000221	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MAPK1—multiple sclerosis	1.48e-05	0.000219	CbGpPWpGaD
Valsartan—ALB—Hemostasis—MAPK1—multiple sclerosis	1.46e-05	0.000217	CbGpPWpGaD
Valsartan—ALB—Metabolism—APOE—multiple sclerosis	1.22e-05	0.000181	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL6—multiple sclerosis	1.14e-05	0.000169	CbGpPWpGaD
Valsartan—ALB—Metabolism—POMC—multiple sclerosis	1.05e-05	0.000155	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—APOE—multiple sclerosis	1e-05	0.000148	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—POMC—multiple sclerosis	8.59e-06	0.000127	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ALB—multiple sclerosis	7.84e-06	0.000116	CbGpPWpGaD
